Nuclea Biotechnologies Initiates Series C Round Targeting $10M | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies has started a Series C financing round targeting $10 million to further its regulatory submissions and for marketing activities, its CEO said today.

The company disclosed in a Form D filed this week with the US Securities and Exchange Commission that it had raised $1.9 million financing round. As a result, it has paid back a note held by six current shareholders in the firm, leaving Nuclea debt-free, CEO Patrick Muraca told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.